Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
Cetuximab
100%
Cyclin-dependent Kinase 6 (CDK6)
100%
Palbociclib
70%
High-risk Human Papillomavirus (HR-HPV)
40%
Placebo
30%
Overall Survival
20%
Platinum Resistance
20%
Recurrent or Metastatic
20%
Randomized Phase II Trial
10%
Efficacy Outcomes
10%
Preclinical Data
10%
Large Reduction
10%
Phase II Trial
10%
Patient Selection
10%
Therapeutic Strategies
10%
Advanced or Metastatic
10%
Risk of Death
10%
Phase 1 Clinical Trial
10%
Predictive Biomarker
10%
Locally Advanced
10%
Cyclin-dependent Kinase 4 (CDK4)
10%
Biomarker Analysis
10%
Locally Recurrent
10%
CDKN2A mutation
10%
Medicine and Dentistry
Head and Neck Squamous Cell Carcinoma
100%
Cetuximab
100%
Cyclin-Dependent Kinase 4
100%
Palbociclib
70%
Biological Marker
40%
Wart Virus
40%
Placebo
30%
Overall Survival
20%
Phase II Trials
20%
Clinical Trial
10%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Squamous Cell Carcinoma
100%
Cetuximab
100%
Cyclin Dependent Kinase 4
100%
Palbociclib
70%
Biological Marker
40%
Human Papillomavirus
40%
Placebo
30%
Overall Survival
20%
Phase II Trials
20%
Clinical Trial
10%